[go: up one dir, main page]

Michon et al., 2006 - Google Patents

Group B streptococcal type II and III conjugate vaccines: physicochemical properties that influence immunogenicity

Michon et al., 2006

View PDF @Full View
Document ID
12862874628273614546
Author
Michon F
Uitz C
Sarkar A
D'Ambra A
Laude-Sharp M
Moore S
Fusco P
Publication year
Publication venue
Clinical and vaccine immunology

External Links

Snippet

Recent efforts toward developing vaccines against group B streptococci (GBS) have focused on increasing the immunogenicity of GBS polysaccharides by conjugation to carrier proteins. However, partial depolymerization of GBS polysaccharides for the production of vaccines is …
Continue reading at journals.asm.org (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48238—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid
    • A61K47/48246—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid drug-peptide, protein or polyamino acid conjugates, i.e. the modifying agent being a protein, peptide, polyamino acid which being linked/complexed to a molecule that being the pharmacologically or therapeutically active agent
    • A61K47/4833—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid drug-peptide, protein or polyamino acid conjugates, i.e. the modifying agent being a protein, peptide, polyamino acid which being linked/complexed to a molecule that being the pharmacologically or therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens

Similar Documents

Publication Publication Date Title
EP0830380B1 (en) Antigenic group b streptococcus type ii and type iii polysaccharide fragments having a 2, 5-anhydro-d-mannose terminal structure and conjugate vaccine thereof
Wessels et al. Structural properties of group B streptococcal type III polysaccharide conjugate vaccines that influence immunogenicity and efficacy
Mawas et al. Immunogenicity in a mouse model of a conjugate vaccine made with a synthetic single repeating unit of type 14 pneumococcal polysaccharide coupled to CRM197
Theilacker et al. Construction and characterization of a Pseudomonas aeruginosa mucoid exopolysaccharide-alginate conjugate vaccine
Benaissa-Trouw et al. Synthetic polysaccharide type 3-related di-, tri-, and tetrasaccharide–CRM197 conjugates induce protection against Streptococcus pneumoniae type 3 in mice
Maira-Litrán et al. Immunochemical properties of the staphylococcal poly-N-acetylglucosamine surface polysaccharide
Safari et al. Identification of the smallest structure capable of evoking opsonophagocytic antibodies against Streptococcus pneumoniae type 14
Paoletti et al. Effects of chain length on the immunogenicity in rabbits of group B Streptococcus type III oligosaccharide-tetanus toxoid conjugates.
Laferriere et al. Streptococcus pneumoniae type 14 polysaccharide-conjugate vaccines: length stabilization of opsonophagocytic conformational polysaccharide epitopes
Gravekamp et al. Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines
Goyette-Desjardins et al. Protection against Streptococcus suis serotype 2 infection using a capsular polysaccharide glycoconjugate vaccine
Gupta et al. Phase 1 evaluation of Vibrio cholerae O1, serotype Inaba, polysaccharide-cholera toxin conjugates in adult volunteers
KR20190103256A (en) Polypeptide-antigen conjugates with unnatural amino acids
Fattom et al. Antigenic determinants of Staphylococcus aureus type 5 and type 8 capsular polysaccharide vaccines
AU2005316864B2 (en) Glycoconjugate vaccines containing peptidoglycan
Boutonnier et al. Preparation, immunogenicity, and protective efficacy, in a murine model, of a conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of Vibrio cholerae O139 bound to tetanus toxoid
Michon et al. Group B streptococcal type II and III conjugate vaccines: physicochemical properties that influence immunogenicity
Kossaczka et al. Vibrio cholerae O139 conjugate vaccines: synthesis and immunogenicity of V. cholerae O139 capsular polysaccharide conjugates with recombinant diphtheria toxin mutant in mice
Rana et al. Development and characterization of Haemophilus influenzae type b conjugate vaccine prepared using different polysaccharide chain lengths
Ravenscroft et al. Glycoconjugate vaccines
Pavliakova et al. Clostridium difficile recombinant toxin A repeating units as a carrier protein for conjugate vaccines: studies of pneumococcal type 14, Escherichia coli K1, and Shigella flexneri type 2a polysaccharides in mice
Guttormsen et al. Rational chemical design of the carbohydrate in a glycoconjugate vaccine enhances IgM-to-IgG switching
Shen et al. Group B Streptococcus capsular polysaccharide-cholera toxin B subunit conjugate vaccines prepared by different methods for intranasal immunization
Yu et al. The Pneumococcal Polysaccharide‐Tetanus Toxin Native C‐Fragment Conjugate Vaccine: The Carrier Effect and Immunogenicity
Grandjean et al. Acid-detoxified Inaba lipopolysaccharide (pmLPS) is a superior cholera conjugate vaccine immunogen than hydrazine-detoxified lipopolysaccharide and induces vibriocidal and protective antibodies